即時血脂檢測市場規模、佔有率和成長分析：按產品類型、應用、適應症、最終用戶和地區分類－2026-2033年產業預測

2024 年全球即時血脂檢測市值為 6.8968 億美元，預計到 2025 年將成長至 7.3658 億美元，到 2033 年將成長至 12.4678 億美元，在預測期（2026-2033 年）內複合年成長率為 6.8%。

全球即時檢測（POC​​）血脂市場正圍繞著使用一次性試劑盒的攜帶式分析儀蓬勃發展，這些分析儀可在診所、藥房等各種場所快速提供膽固醇、三酸甘油酯和脂蛋白檢測結果。心血管疾病發生率的不斷上升使得快速風險評估變得至關重要，而傳統的實驗室檢測流程無法充分滿足這項需求。血脂監測法規核准的核准正在推動市場擴張，促使醫療系統採用攜帶式解決方案，以降低檢測成本並改善服務不足人口的就醫途徑。藥局與POC設備製造商之間的合作已顯著提高了預防性醫療服務的普及率。此外，人工智慧的整合正在深刻地改變這一領域，透過智慧演算法實現血脂譜的快速分析，從而提高準確性，實現異常值的即時預警，簡化工作流程並提升患者照護。

全球即時血脂檢測市場按產品類型、應用、適應症、最終用戶和地區進行細分。依產品類型分類，市場分為「設備」與「耗材」。依應用分類，市場分為「高血脂症」、「高三酸甘油脂血症」、「唐吉爾氏症」、「遺傳性高膽固醇症」和其他。依適應症分類，市場分為脂質和脂蛋白失調、動脈粥狀硬化、肝腎疾病、糖尿病和其他。依最終用戶分類，市場分為醫院、診斷檢查室、診所和居家照護機構。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球即時血脂檢測市場成長要素

隨著慢性病盛行率的不斷上升，醫療服務提供者對更快速、更便捷的現場血脂檢測提出了更高的要求，以便及時制定治療方案。即時檢測平台無需依賴中心檢查室即可提供即時結果，使患者免於等待，並幫助臨床醫生加快治療計劃的製定。這種快速反應不僅提高了患者的用藥依從性，而且促進了疾病管理的預防性策略，不受不同醫療機構臨床資源差異的影響。因此，分散式血脂檢測的臨床意義日益凸顯，吸引了醫院、基層醫療機構和社區醫療舉措的注意。即時血脂檢測解決方案的廣泛應用正在推動全球範圍內的醫療服務可近性提升，並改善心血管風險監測。

全球即時血脂檢測市場面臨的限制因素

精準血脂檢測所需的高級組件，例如高精度感測器和整合數據分析功能，通常會導致設備成本增加。對於預算緊張的小規模診所和醫療機構而言，高昂的價格構成了一項重大挑戰，因為這些機構的資金通常用於基本醫療服務，而非尖端診斷技術。因此，這些先進血脂檢測解決方案的普及程度參差不齊，並且經常因資金短缺而延誤。這阻礙了整體市場成長，並限制了分散式血脂檢測的覆蓋範圍，尤其是在全球農村和醫療服務不足的地區。

全球即時血脂檢測市場趨勢

全球即時血脂檢測市場正呈現出顯著的數位整合趨勢，醫療服務提供者擴大將血脂分析儀整合到電子健康記錄和遠端醫療平台中。這種無縫連接有助於與臨床醫生即時共用數據，最大限度地減少診斷延遲，增強個人化治療方案，並進一步提高患者參與度。隨著互通性標準的不斷發展，儀器製造商正在其設備中整合連接模組以及安全的雲端介面。這支持了跨各種醫療機構（包括醫院、基層醫療診所和遠端監測網路）的協作式醫療模式。這種轉變正在推動以數據驅動的方式進行心血管風險管理，最終改善長期健康並永續的醫療實踐。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球即時血脂檢測市場規模：依產品類型分類

• 裝置
  • 單參數分析儀
  • 多參數分析儀
• 消耗品
  • 測試條
  • 墨水匣
  • 試劑
  • 校準器

全球即時血脂檢測市場規模：依應用領域分類

• 高血脂症
• 高三酸甘油脂血症
• 唐吉爾氏症
• 遺傳性高膽固醇症
• 其他

全球即時血脂檢測市場規模：依適應症分類

• 脂質和脂蛋白異常
• 動脈硬化
• 肝腎疾病
• 糖尿病
• 其他

全球即時血脂檢測市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 診所
• 居家醫療

全球即時血脂檢測市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Becton Dickinson and Company
• Quidel Corporation（QuidelOrtho）
• Bio-Rad Laboratories Inc.
• Horiba ABX SAS
• Randox Laboratories Ltd.
• Sekisui Diagnostics LLC
• Fisher Scientific International Inc.
• Nova Biomedical Corporation
• SD Biosensor Inc.
• Sinocare Inc.
• VivaChek Biotech（Hangzhou）Co. Ltd.
• Callegari Srl
• MiCoBio Inc.
• Menarini Group
• Cobas（Roche）
• Orion Diagnostica Oy
• Cholestech Corporation

結論與建議

Global Point Of Care Lipid Test Market size was valued at USD 689.68 Million in 2024 and is poised to grow from USD 736.58 Million in 2025 to USD 1246.78 Million by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The global point-of-care (POC) lipid test market is evolving around portable analyzers that utilize disposable cartridges to provide rapid cholesterol, triglyceride, and lipoprotein results at various settings, including clinics and pharmacies. Growing cardiovascular disease rates necessitate swift risk assessments that traditional lab processes struggle to meet. Regulatory endorsement of lipid monitoring has propelled market expansion, compelling health systems to adopt portable solutions that lower testing costs and enhance accessibility for underserved populations. Collaborations between pharmacies and POC device manufacturers have demonstrated significant increases in preventive treatment uptake. Moreover, the integration of AI is transforming this landscape by enabling quick interpretation of lipid profiles through smart algorithms, improving accuracy, facilitating real-time alerts for abnormal values, and streamlining workflows to enhance patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Point Of Care Lipid Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Point Of Care Lipid Test Market Segments Analysis

The global point-of-care lipid test market is segmented by product type, application, indication, end user and region. Based on product type, the market is segmented into Instruments and Consumables. Based on application, the market is segmented into Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Familial Hypercholesterolemia and Others. Based on indication, the market is segmented into Lipid & Lipoprotein Disorders, Atherosclerosis, Liver & Renal Diseases, Diabetes Mellitus and Others. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Clinics and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Point Of Care Lipid Test Market

The increasing prevalence of chronic diseases is driving healthcare providers to seek faster, on-site lipid testing to make timely therapeutic decisions. Point-of-care platforms deliver immediate results without reliance on central laboratories, allowing patients to avoid waiting and enabling clinicians to expedite treatment plans. This rapid response not only enhances patient adherence but also fosters a preventive approach to disease management, regardless of varying clinical resources across different settings. Consequently, the clinical significance of decentralized lipid testing is becoming increasingly apparent, attracting interest from hospitals, primary care clinics, and community health initiatives alike. This growing adoption of point-of-care lipid solutions promotes broader access and improves cardiovascular risk monitoring globally.

Restraints in the Global Point Of Care Lipid Test Market

The advanced components required for accurate lipid testing, such as high-precision sensors and integrated data analytics, often result in a higher cost for these devices. This elevated price point poses a significant challenge for small clinics and facilities operating under strict budget constraints, where financial resources are typically allocated to essential services rather than cutting-edge diagnostic technologies. Consequently, the adoption of these advanced lipid testing solutions remains inconsistent, and limited funding frequently delays their implementation. This hinders overall market growth and restricts the reach of decentralized lipid testing options, particularly in rural areas and underserved communities worldwide.

Market Trends of the Global Point Of Care Lipid Test Market

The Global Point Of Care Lipid Test market is experiencing a significant trend towards digital integration, as healthcare providers increasingly incorporate lipid analyzers into electronic medical records and telehealth platforms. This seamless connectivity facilitates real-time data sharing with clinicians, minimizing diagnostic delays and enhancing personalized treatment approaches while encouraging greater patient engagement. As interoperability standards evolve, device manufacturers are embedding connectivity modules within their instruments, along with secure cloud interfaces, which support collaborative care models across various healthcare settings, including hospitals, primary clinics, and remote monitoring networks. This shift is driving a data-driven approach to cardiovascular risk management, ultimately fostering improved long-term health outcomes and sustainable practices.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Point of Care Lipid Test Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Instruments
  • Single-Parameter Analyzers
  • Multi-Parameter Analyzers
• Consumables
  • Test Strips
  • Cartridges
  • Reagents
  • Calibrators

Global Point of Care Lipid Test Market Size by Application & CAGR (2026-2033)

• Market Overview
• Hyperlipidemia
• Hypertriglyceridemia
• Tangier Disease
• Familial Hypercholesterolemia
• Others

Global Point of Care Lipid Test Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Lipid & Lipoprotein Disorders
• Atherosclerosis
• Liver & Renal Diseases
• Diabetes Mellitus
• Others

Global Point of Care Lipid Test Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Clinics
• Home Care Settings

Global Point of Care Lipid Test Market Size & CAGR (2026-2033)

• North America (Product Type, Application, Indication, End User)
  • US
  • Canada
• Europe (Product Type, Application, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Indication, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quidel Corporation (QuidelOrtho)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horiba ABX SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fisher Scientific International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SD Biosensor Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinocare Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VivaChek Biotech (Hangzhou) Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Callegari Srl
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MiCoBio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Menarini Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cobas (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Diagnostica Oy
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cholestech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations